WellSurvivor Breast BR-3
WellSurvivor Breast BR-3 is a multi-supplement routine specifically researched to support long-term nutritional needs and wellness goals of estrogen-positive, HER2-positive (ER+/HER2+) or triple positive, premenopausal breast cancer survivors who are not currently taking any maintenance medications.
Healthcare Provider Documentation & Information:
The information below is intended for healthcare provider reference only. It summarizes supporting clinical research, ingredient rationale, and evidence-based considerations relevant to professional evaluation. This content is not intended for customer-facing use. This content is for informational and educational purposes only.
Bone Health
Vitamin D₃ (2,000 IU), Vitamin K₂ (100 µg), Magnesium (Bisglycinate 90 mg)
• Supports bone density & calcium balance — Endocrine guidelines emphasize sufficient calcium & vitamin D for skeletal health maintenance. endocrine.org +1
• Breast cancer treatments like chemotherapy-induced menopause and ovarian suppression accelerate bone loss; guidelines advocate calcium + vitamin D supplementation to prevent osteoporosis. endocrine.org
• Vitamin K₂ enhances vitamin D’s effect on bone mineralization: meta-analysis shows K₂ improves lumbar spine BMD and, when heterogeneity is accounted for, reduces fracture risk. PMC9403798
• Higher magnesium intake was associated with higher bone mineral density (BMD) PubMed 34666201
• These nutrients are non-estrogenic at these doses; no evidence of activating ER+ breast cancer pathways from these levels.
Metabolic & Thyroid Function (Trace Minerals)
Zinc (8 mg), Selenium (50 µg), Iodine (50 µg), Manganese (1 mg), Chromium (100 µg), Molybdenum (45 µg)
• Core enzyme cofactors — Zinc → Cu/Zn-SOD (SOD1) supports cellular antioxidant defense PubMed 29186856
• Manganese → Mn-SOD (SOD2) is the chief mitochondrial ROS scavenger PubMed 22072939
• Selenium → selenoproteins (GPx, TrxR, deiodinases) linking redox control, immunity, and thyroid metabolism PubMed 22072939
• Molybdenum → cofactor for xanthine oxidase, sulfite oxidase, aldehyde oxidase (NIH ODS fact sheet for clinicians).
• Thyroid hormone synthesis (iodine): Iodine is required for T4/T3 production; adult RDA ≈150 µg/day and UL 1,100 µg/day (NIH ODS Iodine).
• Selenium & cancer-relevant outcomes: Higher selenium status is associated with lower overall cancer risk PubMed 26786590. In breast cancer, lower serum selenium/SELENOP relates to worse survival PubMed 33809461, PubMed 29043463.
• Iodine & breast tissue: Clinical studies in fibrocystic breast disease show symptomatic benefit with iodine PubMed 8221402, PMC11700310.
• HR⁺ survivorship context: At physiologic (RDA/AI) doses, these trace minerals are non-estrogenic and commonly used in survivorship care.
Antioxidant & Cellular Protection
Vitamin C (300 mg), EGCG (Green Tea Extract) 400 mg, Lycopene (8 mg), DIM (Diindolylmethane) 300 mg
• Vitamin C: Potent antioxidant and immune supporter PMC5707683
• EGCG: Meta-analysis suggests green tea may reduce breast cancer recurrence DOI 10.3390/nu10121886 and does not alter tamoxifen metabolism PMC7595994.
• Lycopene: Anti-proliferative carotenoid PMC4317951, PMC9741066.
• DIM: Supports healthy estrogen metabolism, non-estrogenic action PMC5059820.
Immune Function & Wellness (Medicinal Mushrooms)
Turkey Tail, Reishi, Maitake, Lion’s Mane, Cordyceps, Chaga, Oyster (standardized extracts)
β-Glucans and extracts shown to enhance immune surveillance and support NK activity: 19515245, PMC10711352, Turkey Tail Trial, Reishi Trial, Maitake Trial, Lion’s Mane RCT, Cordyceps Review, Chaga, Oyster Study.
These mushroom extracts are non-estrogenic and have no reported adverse interactions with hormonal therapies.
Stress Resilience & Energy
Rhodiola rosea (250 mg), CoQ10 (Ubiquinone/Ubiquinol)
• Rhodiola: Adaptogenic herb shown to reduce fatigue and improve mood in cancer survivorship PMC6208354; non-estrogenic mechanism via stress-response pathways AACR.
• Salidroside (active compound) induces apoptosis and cell-cycle arrest in breast cancer lines without estrogen activation Salidroside Study.
• CoQ10: Explored for cardioprotection in HER2⁺ therapy contexts; may reduce anthracycline-induced cardiotoxicity PMC10652675, NCI PDQ; antioxidant and mitochondrial support MDPI Antioxidants Review.